Financial PerformanceVivitrol sales of $113.7M were well above expectations, contributing to strong 3Q24 results.
Market OpportunityALKS-2680 is the only orexin-2 receptor agonist to demonstrate efficacy in narcolepsy type I, narcolepsy type II, and idiopathic hypersomnia conditions in a Phase 1b trial.
Stock PerformanceAnalyst reiterates an Outperform rating and raises the price target from $35 to $40, indicating confidence in the stock's performance.